The research
behind LionBio
We're developing a nasal formulation of semaglutide in a biodegradable polymer nanoparticle. Academic animal studies informed the approach. Our current work focuses on drug distribution, release, and preparation for clinical studies.
Stage: preclinical development
Where we started
LionBio's approach grew out of academic studies of nasal peptide delivery and the biology of the olfactory bulb.
The olfactory lining in the upper nose connects to this brain region through the olfactory nerves. The bulb processes information about smell and communicates with circuits involved in feeding and metabolism.4 In mice, it also contains cells that produce GLP-1 and cells that respond to it. A published study found that activating GLP-1 receptors here increased insulin release in response to glucose.5
This biology gives us a reason to investigate nasal peptide delivery. The academic work behind LionBio examined how formulation and delivery route affected drug-label distribution, body weight and retching in animals.1
Why the nanoparticle matters
Researchers compared free tirzepatide with tirzepatide encapsulated in biodegradable nanoparticles, both delivered through the nose. Male mice with diet-induced obesity received the same dose of drug each day for eight days.1
Body weight fell more in the nanoparticle group, while free nasal tirzepatide produced little change under the same conditions. The comparison supports a role for formulation in the observed response, though it does not establish where the active drug acted.1
Weight change in mice
In a separate four-week study, researchers tracked mice receiving daily nasal tirzepatide nanoparticles, injected tirzepatide or vehicle. Average body weight in the nasal group fell by 26.7% from its starting level. Both drug groups also showed reductions in fat mass.1
Semaglutide
The same academic research also tested nasal semaglutide nanoparticles. Over six days, body weight fell in the treated group while vehicle controls remained close to their starting weight. The experiment included seven treated mice and six vehicle controls.1
LionBio's current semaglutide research builds on these academic experiments with studies of drug exposure and biological response.
Distribution and tolerability
Tracing distribution
Researchers detected a fluorescent label in the olfactory bulb one hour after nasal dosing of labelled tirzepatide nanoparticles in mice. The images below show one representative animal from each group.1
The experiment tracks the label. Measuring how much intact drug reaches the tissue requires a different assay, and remains a question for further study.

Retching in minks
In an exploratory single-dose study, female minks receiving nasal semaglutide nanoparticles had fewer retching episodes than those receiving injected semaglutide during a two-hour observation period.123
Routes were studied at different doses. This observation does not establish an overall tolerability advantage.
Unpublished animal research, not peer reviewed. Results may not translate to people.
Where we are, and where we're going
-
Complete · 2024
Academic studies
Initial animal studies informed the formulation and delivery approach.
-
Underway · Q3 2026
Rat studies
Measuring semaglutide in blood and brain after nasal dosing.
-
Planned · Q1 2027
Non-human primate studies
Studying nasal delivery and drug exposure in non-human primates.
-
In progress · Q4 2026
Formulation and manufacturing
Developing a consistent formulation and a process for larger batches.
-
Target: Q4 2027
First clinical study
Preparing to test the formulation in people.
The clinical timeline depends on preclinical results, manufacturing readiness, and the required regulatory and ethics approvals.
LionBio's nasal formulation is investigational. Its safety and effectiveness in people have not been established, and it is not approved for human use.
Research from the Leong lab
Our nanoparticle approach came out of Kam Leong's lab at Columbia University, which has spent decades on drug and gene delivery, nonviral gene editing, scalable nanoparticle manufacturing and biomaterials. A selection of the lab's papers, by area.
Drug and gene delivery +
- Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy · Nature Medicine, 1999
- Multifunctional nanorods for gene delivery · Nature Materials, 2003
- A programmable encapsulation system improves delivery of therapeutic bacteria in mice · Nature Biotechnology, 2022
- Targeted protein degradation via cellular trafficking of nanoparticles · Nature Nanotechnology, 2024
Nonviral gene editing +
- Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide · PNAS, 2018
- Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects · Science Advances, 2020
- A versatile nonviral delivery system for multiplex gene editing in the liver · Advanced Materials, 2020
- Brain nucleic acid delivery and genome editing via focused ultrasound-mediated blood-brain barrier opening and long-circulating nanoparticles · ACS Nano, 2024
Nanotherapeutics manufacturing +
- Scalable fabrication of size-controlled chitosan nanoparticles for oral delivery of insulin · Biomaterials, 2017
- A versatile and robust platform for the scalable manufacture of biomimetic nanovaccines · Advanced Science, 2021
- Flash technology-based self-assembly in nanoformulation: from fabrication to biomedical applications · Materials Today, 2021
- Scalable biomimetic SARS-CoV-2 nanovaccines with robust protective immune responses · Signal Transduction and Targeted Therapy, 2022
Biomaterials for regenerative medicine +
- Nanotopography as modulator of human mesenchymal stem cell function · Biomaterials, 2012
- The effect of substrate topography on direct reprogramming of fibroblasts to induced neurons · Biomaterials, 2014
- A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease · Science Advances, 2022
- Design of therapeutic biomaterials to control inflammation · Nature Reviews Materials, 2022
- Nanoparticulate cell-free DNA scavenger for treating inflammatory bone loss in periodontitis · Nature Communications, 2022
- Therapeutic nanocarriers inhibit chemotherapy-induced breast cancer metastasis · Advanced Science, 2022
- Wan Q, Li Z, Ding S, Shi M-Y, et al. GLP-1 drug targets the olfactory bulb to combat obesity. Manuscript in preparation (Peking University, Columbia University, University of Science and Technology of China). Unpublished academic study, not peer reviewed; animal data summarised here.
- Horn CC, et al. Why can't rodents vomit? A comparative behavioral, anatomical, and physiological study. PLoS One 2013;8:e60537. PubMed
- Zhang F, et al. Value of mink vomit model in study of anti-emetic drugs. World J Gastroenterol 2006;12:1300-1302. PubMed
- Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64:614-628. PubMed
- Montaner M, Denom J, Simon V, et al. A neuronal circuit driven by GLP-1 in the olfactory bulb regulates insulin secretion. Nat Commun 2024;15:6941. DOI
Questions about the research?
Follow our progress
Research updates and news from the team.
For research, partnerships or investor inquiries: hello@lion.bio